Kristen Ambrose sold $1.1M of VRTX
SVP & Chief Accounting Officer at VERTEX PHARMACEUTICALS INC / MA. 2,195 shares at an average of $484.87, traded Feb 17, 2026, filed Feb 19, 2026.
Score components
- +15RoleOfficer
- +25Trade size$1.1M at market
- +5Share of holdings soldSold 22% of holdings
- +15Cluster11 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000875320-26-000080, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Feb 17, 2026 | AGrant or award Common Stock10b5-1 | +1,809 | $0.00 | $0 | 10,543 | Feb 19, 2026 |
| Feb 17, 2026 | FTax withholding Common Stock10b5-1 | -598 | $483.75 | $289k | 9,945 | Feb 19, 2026 |
| Feb 17, 2026 | SOpen-market sale Common Stock10b5-1 | -1,557 | $489.46 | $762k | 8,388 | Feb 19, 2026 |
| Feb 18, 2026 | SOpen-market sale Common Stock10b5-1 | -638 | $473.68 | $302k | 7,750 | Feb 19, 2026 |
Related signals
Other insiders at VERTEX PHARMACEUTICALS INC / MA and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 20Weak | VERTEX PHARMACEUTICALS INC / MA | Carmen Bozic EVP and CMO | $1.1M 2,329 shares | -7% | |
| 35Weak | VERTEX PHARMACEUTICALS INC / MA | Carmen Bozic EVP and CMO | $1.1M 2,329 shares | -6% | |
| 40Moderate | VERTEX PHARMACEUTICALS INC / MA | Duncan McKechnie EVP, Chief Commercial Officer | $1.3M 2,633 shares | -17% | |
| 40Moderate | VERTEX PHARMACEUTICALS INC / MA | Duncan McKechnie EVP, Chief Commercial Officer | $1.2M 2,437 shares | -14% | |
| 27Weak | VERTEX PHARMACEUTICALS INC / MA | Joy Liu EVP and Chief Legal Officer | $442k 892 shares | -4% | |
| 35Weak | VERTEX PHARMACEUTICALS INC / MA | Carmen Bozic EVP and CMO | $1.1M 2,329 shares | -6% | |
| 55Moderate | VERTEX PHARMACEUTICALS INC / MA | Reshma Kewalramani CEO & President | $20M 40,000 shares | -29% | |
| 21Weak | VERTEX PHARMACEUTICALS INC / MA | Kristen Ambrose SVP & Chief Accounting Officer | $173k 357 shares | -5% | |
| 20Weak | VERTEX PHARMACEUTICALS INC / MA | Kristen Ambrose SVP & Chief Accounting Officer | $108k 223 shares | -3% | |
| 24Weak | VERTEX PHARMACEUTICALS INC / MA | Edward Morrow Atkinson III EVP, Chief Technical Ops. Off. | $325k 668 shares | -3% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.